Breast Cancer: Targets and Therapy
Volume 10, 2018 - Issue
Open access
201
Views
3
CrossRef citations to date
0
Altmetric
Original Research
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
Anna Forsythe1 Purple Squirrel Economics, New York, NYCorrespondence[email protected]
, David Chandiwana2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
, Janina Barth3 Novartis Pharma GmbH, Nuremberg, Germany
, Marroon Thabane4 Novartis Pharmaceuticals Incorporated, Dorval, QC, Canada
, Johan Baeck2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
& Gabriel Tremblay1 Purple Squirrel Economics, New York, NY
Pages 69-78
|
Published online: 04 May 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.